<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TAFINLAR- dabrafenib mesylate capsule </strong><br>GlaxoSmithKline LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TAFINLAR safely and effectively.  See full prescribing information for TAFINLAR.<br><br><br>TAFINLAR (dabrafenib) capsules, for oral use<br>Initial U.S. Approval: 2013</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="80%">
<col width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="Highlighta">Indications and Usage (1.2) </p></td>
<td><p class="Highlighta">01/2014 </p></td>
</tr>
<tr>
<td><p class="Highlighta">Dosage and Administration (2.1-2.3) </p></td>
<td><p class="Highlighta">01/2014 </p></td>
</tr>
<tr class="Botrule Last">
<td><p class="Highlighta">Warnings and Precautions (5-5.9, 5.11) </p></td>
<td><p class="Highlighta">01/2014 </p></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span> with BRAF V600E mutation as detected by an FDA-approved test. (<a href="#ID_ec0db0a0-9063-4987-a68d-4c2e4ad9dc81">1.1</a>, <a href="#ID_cf020e42-1ac7-4854-8c93-2e3f0df6e7e0">2.1</a>)</dd>
<dt>•</dt>
<dd>TAFINLAR in combination with trametinib is indicated for the treatment of patients with unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span> with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib. (<a href="#ID_5e69ef6d-1464-4172-94fe-d59003bc0e3f">1.2</a>, <a href="#ID_cf020e42-1ac7-4854-8c93-2e3f0df6e7e0">2.1</a>, <a href="#ID_a176681f-f182-4e19-823d-6ec3504dc811">14.2</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">Limitation of Use: </span>TAFINLAR is not indicated for treatment of patients with wild-type BRAF melanoma. (<a href="#ID_9305612d-6967-4e9c-908c-4548a937d505">1.3</a>, <a href="#ID_3101ce94-a4ac-4a43-9217-49ff3320aadf">5.2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR as a single agent. Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with TAFINLAR in combination with trametinib. (<a href="#ID_cf020e42-1ac7-4854-8c93-2e3f0df6e7e0">2.1</a>)</dd>
<dt>•</dt>
<dd>The recommended dose of TAFINLAR is 150 mg orally twice daily as a single agent or in combination with trametinib 2 mg orally once daily. Take TAFINLAR at least 1 hour before or at least 2 hours after a meal. (<a href="#ID_50325ded-903b-4663-83ae-0598c41c7e6d">2.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 50 mg, 75 mg. (<a href="#ID_60cae42a-5210-44a2-8797-bc0caeb26af1">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#ID_eb612def-e914-42ba-abeb-3507a524167f">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib. Monitor patients for new malignancies prior to initiation of therapy, while on therapy, and following discontinuation of TAFINLAR or the combination therapy. (<a href="#ID_246de61f-b61d-4b3e-90d2-307e38395339">5.1</a>, <a href="#ID_97f8af8c-3875-4a57-ba45-d35c4968dd54">2.3</a>)</dd>
<dt>•</dt>
<dd>Tumor Promotion in BRAF Wild-Type Melanoma: Increased cell proliferation can occur with BRAF inhibitors. (<a href="#ID_3101ce94-a4ac-4a43-9217-49ff3320aadf">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>: Major hemorrhagic events can occur in patients receiving TAFINLAR in combination with trametinib. Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#ID_caee0e32-c757-42c4-a6da-592edfb671fe">5.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span>: <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> can occur in patients receiving TAFINLAR in combination with trametinib. (<a href="#ID_74245e1d-0448-45c3-8b6f-7fff6fbe1853">5.4</a>, <a href="#ID_97f8af8c-3875-4a57-ba45-d35c4968dd54">2.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Assess LVEF before treatment with TAFINLAR in combination with trametinib, after one month of treatment, then every 2 to 3 months thereafter. (<a href="#ID_d5ee6127-d7eb-4cbe-a30c-0f960552bd9f">5.5</a>, <a href="#ID_97f8af8c-3875-4a57-ba45-d35c4968dd54">2.3</a>)</dd>
<dt>•</dt>
<dd>Ocular Toxicities: Perform ophthalmologic evaluation for any <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. (<a href="#ID_eced3634-85be-46cf-8ec1-ee16a00f1a21">5.6</a>, <a href="#ID_97f8af8c-3875-4a57-ba45-d35c4968dd54">2.3</a>)</dd>
<dt>•</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Febrile Reactions</span>: Incidence and severity of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> are increased with TAFINLAR in combination with trametinib. (<a href="#ID_10722c5d-9921-4c25-9ea2-8fd389f75a34">5.7</a>, <a href="#ID_97f8af8c-3875-4a57-ba45-d35c4968dd54">2.3</a>)</dd>
<dt>•</dt>
<dd>Serious Skin Toxicity: Monitor for skin toxicities and for <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infections</span>. Discontinue for intolerable Grade 2, or Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> not improving within 3 weeks despite interruption of TAFINLAR. (<a href="#ID_7400742d-d2d3-4b14-a8a5-d6fe2958e080">5.8</a>, <a href="#ID_97f8af8c-3875-4a57-ba45-d35c4968dd54">2.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>: Monitor serum glucose levels in patients with pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. (<a href="#ID_d11f3c57-84a6-407f-a170-bdff85815d74">5.9</a>)</dd>
<dt>•</dt>
<dd>Glucose-6-Phosphate Dehydrogenase Deficiency: Closely monitor for <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. (<a href="#ID_74168113-455a-4c37-8044-695783788ef8">5.10</a>)</dd>
<dt>•</dt>
<dd>Embryofetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus. TAFINLAR may render hormonal contraceptives less effective and an alternative method of contraception should be used. (<a href="#ID_6bc15508-c426-4344-a5c7-d5b5b6a1c501">5.11</a>, <a href="#ID_af99b01e-2247-48c2-8aef-cc255145d414">8.1</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Most common adverse reactions (≥20%) for TAFINLAR as a single agent are <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, and palmar-plantar erythrodysesthesia syndrome. (<a href="#ID_bab2577d-bf86-45c1-a1f3-8658c6d2b154">6.1</a>)</dd>
<dt>•</dt>
<dd>Most common adverse reactions (≥20%) for TAFINLAR in combination with trametinib are <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. (<a href="#ID_bab2577d-bf86-45c1-a1f3-8658c6d2b154">6.1</a>) </dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Avoid concurrent administration of strong inhibitors of CYP3A4 or CYP2C8. (<a href="#ID_5be5734d-a26e-465f-b84b-411935911d37">7.1</a>)</dd>
<dt>•</dt>
<dd>Avoid concurrent administration of strong inducers of CYP3A4 or CYP2C8. (<a href="#ID_5be5734d-a26e-465f-b84b-411935911d37">7.1</a>)</dd>
<dt>•</dt>
<dd>Concomitant use with agents that are sensitive substrates of CYP3A4, CYP2C8, CYP2C9, CYP2C19, or CYP2B6 may result in loss of efficacy of these agents. (<a href="#ID_e4fbfff8-381d-41cc-8829-4f644defb184">7.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing Mothers: Discontinue drug or nursing. (<a href="#ID_47509c9d-0d8e-44d3-bad3-26b7e98dc215">8.3</a>)</dd>
<dt>•</dt>
<dd>Females and Males of Reproductive Potential: Advise female patients to use highly effective contraception during treatment and for 2 weeks following discontinuation of treatment. Advise male patients of potential risk for impaired spermatogenesis. (<a href="#ID_3a52d010-5f75-4401-be38-dd1b79b4ccec">8.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 BRAF V600E Mutation-Positive Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="XmChange">1.2 BRAF V600E or V600K Mutation-Positive Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Patient Selection</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dosing</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Modifications</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 New Primary Malignancies</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Tumor Promotion in BRAF Wild-Type Melanoma</a></h2>
<h2><a href="#section-5.3" class="toc"><span class="XmChange">5.3 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="XmChange">5.4 <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange">5.5 <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="XmChange">5.6 Ocular Toxicities</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Febrile Reactions</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="XmChange">5.8 Serious Skin Toxicity</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Glucose-6-Phosphate Dehydrogenase Deficiency</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Embryofetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effects of Other Drugs on Dabrafenib</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effects of Dabrafenib on Other Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Trametinib</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 BRAF V600E Mutation-Positive Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 BRAF V600E or V600K Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_7c0c13ef-f98e-4a87-953f-5a6b57911b31"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ec0db0a0-9063-4987-a68d-4c2e4ad9dc81"></a><a name="section-1.1"></a><p></p>
<h2>1.1 BRAF V600E Mutation-Positive Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></h2>
<p class="First">TAFINLAR<span class="Sup">®</span> as a single agent is indicated for the treatment of patients with unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span> with BRAF V600E mutation as detected by an FDA-approved test.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5e69ef6d-1464-4172-94fe-d59003bc0e3f"></a><a name="section-1.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.2 BRAF V600E or V600K Mutation-Positive Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">TAFINLAR, in combination with trametinib, is indicated for the treatment of patients with unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span> with BRAF V600E or V600K mutations, as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate <span class="Italics">[see Clinical Studies (14.2)]</span>. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9305612d-6967-4e9c-908c-4548a937d505"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitation of Use</h2>
<p class="First">TAFINLAR is not indicated for treatment of patients with wild-type BRAF melanoma <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_35013101-7249-43f9-b0e5-c1b84c6f7d52"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cf020e42-1ac7-4854-8c93-2e3f0df6e7e0"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Patient Selection</h2>
<p class="First" style="border-left:1px solid;">Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR as a single agent <span class="Italics">[see Warnings and Precautions (5.2)]</span>. <span class="XmChange">Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with TAFINLAR in combination with trametinib.</span> Information on FDA-approved tests for the detection of BRAF V600 mutations in melanoma is available at: <a href="http://www.fda.gov/CompanionDiagnostics">http://www.fda.gov/CompanionDiagnostics</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_50325ded-903b-4663-83ae-0598c41c7e6d"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dosing</h2>
<p class="First">The recommended dosage regimens of TAFINLAR are:</p>
<dl>
<dt>•</dt>
<dd>150 mg orally taken twice daily, approximately 12 hours apart, as a single agent</dd>
<dt>•</dt>
<dd><span class="XmChange">150 mg orally taken twice daily, approximately 12 hours apart, in combination with trametinib 2 mg orally taken once daily </span></dd>
</dl>
<p style="border-left:1px solid;">Continue treatment until disease progression or unacceptable toxicity occurs. Take TAFINLAR as a single agent, or <span class="XmChange">TAFINLAR in combination with trametinib, at least 1 hour before or 2 hours after a meal</span><span class="Italics">[see Clinical Pharmacology (12.3)]</span>. Do not take a missed dose of TAFINLAR within 6 hours of the next dose of TAFINLAR. Do not open, crush, or break TAFINLAR capsule.</p>
<p style="border-left:1px solid;"><span class="XmChange">When administered in combination with trametinib, take the once-daily dose of trametinib at the same time each day with either the morning dose or the evening dose of TAFINLAR.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_97f8af8c-3875-4a57-ba45-d35c4968dd54"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Modifications</h2>
<p class="First"><span class="Underline">For New Primary Cutaneous Malignancies:</span> No dose modifications are required<span class="Italics">.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline">For New Primary Non-Cutaneous Malignancies:</span> Permanently discontinue TAFINLAR in patients who develop RAS mutation-positive non-cutaneous malignancies. If used in combination with trametinib, no dose modifications are required for trametinib in patients who develop non-cutaneous malignancies.</span></p>
<a name="_RefID0EHCAE"></a><table width="100%">
<caption><span>Table 1. Recommended Dose Reductions </span></caption>
<col width="28%">
<col width="72%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="bottom"><dl>
<dt> </dt>
<dd><span class="XmChange"><span class="Bold">Dose Reductions for TAFINLAR When Administered as a Single Agent or in Combination With Trametinib</span></span></dd>
</dl></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">First Dose Reduction </span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">100 mg orally twice daily</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">Second Dose Reduction</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">75 mg orally twice daily</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">Third Dose Reduction</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">50 mg orally twice daily</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">Subsequent Modification</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">Permanently discontinue TAFINLAR if unable to tolerate 50 mg orally twice daily</span></dd>
</dl></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="bottom"><dl>
<dt> </dt>
<dd><span class="XmChange"><span class="Bold">Dose Reductions for Trametinib When Administered in Combination With TAFINLAR</span></span></dd>
</dl></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">First Dose Reduction </span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">1.5 mg orally once daily</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">Second Dose Reduction</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">1 mg orally once daily</span></dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">Subsequent Modification</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="XmChange">Permanently discontinue if unable to tolerate trametinib 1 mg orally once daily</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<a name="_RefID0EBHAE"></a><table width="100%">
<caption><span>Table 2. Recommended Dose Modifications for TAFINLAR as a Single Agent and for TAFINLAR and Trametinib Administered in Combination</span></caption>
<col width="38%">
<col width="31%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Severity of Adverse</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Reaction<span class="Sup">a</span></span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">TAFINLAR<span class="Sup">b</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Trametinib</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">(When Used in Combination)<span class="Sup">b,c</span></span></span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Febrile drug reaction</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> of 101.3°F to 104°F</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold TAFINLAR until <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> resolves. Then resume at same or lower dose level.</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Do not modify the dose of trametinib.</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> higher than 104°F</span></dd>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> complicated by <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></span></dd>
</dl></td>
<td class="Botrule Lrule Rrule">
<dl>
<dt>•</dt>
<dd><span class="XmChange">Withhold TAFINLAR until <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> resolves. Then resume at a lower dose level. </span></dd>
</dl>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Or</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">Permanently discontinue TAFINLAR.</span></dd>
</dl>
</td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold trametinib until <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> resolves. Then resume trametinib at same or lower dose level.</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Cutaneous</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Intolerable Grade 2 skin toxicity </span></dd>
<dt>•</dt>
<dd><span class="XmChange">Grade 3 or 4 skin toxicity</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold TAFINLAR for up to 3 weeks.</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved, resume at a lower dose level.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved, permanently discontinue.</span></dd>
</dl>
</td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold trametinib for up to 3 weeks.</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved, resume at a lower dose level. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved, permanently discontinue.</span></dd>
</dl>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Cardiac</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Asymptomatic, absolute decrease in LVEF of 10% or greater from baseline and is below institutional lower limits of normal (LLN) from pretreatment value</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Do not modify the dose of TAFINLAR.</span></p></td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold trametinib for up to 4 weeks.</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved to normal LVEF value, resume at a lower dose level. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved to normal LVEF value, permanently discontinue.</span></dd>
</dl>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Symptomatic <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span></span></dd>
<dt>•</dt>
<dd><span class="XmChange">Absolute decrease in LVEF of greater than 20% from baseline that is below LLN</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold TAFINLAR, if improved, then resume at the same dose.</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Permanently discontinue trametinib.</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Uncomplicated DVT or PE</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Do not modify the dose of TAFINLAR.</span></p></td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold trametinib for up to 3 weeks.</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved to Grade 0-1, resume at a lower dose level. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved, permanently discontinue.</span></dd>
</dl>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Life Threatening PE</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Permanently discontinue TAFINLAR.</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Permanently discontinue trametinib.</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First" style="border-left:1px solid;"><span class="XmChange">Ocular Toxicities</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Grade 2-3 retinal pigment epithelial detachments (RPED)</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Do not modify the dose of TAFINLAR.</span></p></td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold trametinib for up to 3 weeks.</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved to Grade 0-1, resume at a lower dose level. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved, permanently discontinue.</span></dd>
</dl>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal vein occlusion</span></span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Do not modify the dose of TAFINLAR.</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Permanently discontinue trametinib.</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> and <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span></span></dd>
</dl></td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold TAFINLAR for up to 6 weeks. </span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved to Grade 0-1, then resume at the same dose. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved, permanently discontinue.</span></dd>
</dl>
</td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Do not modify the dose of trametinib.</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Pulmonary</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span>/<span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span></span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Do not modify the dose of TAFINLAR.</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Permanently discontinue trametinib.</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Other</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Intolerable Grade 2 adverse reactions</span></dd>
<dt>•</dt>
<dd><span class="XmChange">Any Grade 3 adverse reaction</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold TAFINLAR.</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved to Grade 0-1, resume at a lower dose level. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved, permanently discontinue.</span></dd>
</dl>
</td>
<td class="Botrule Lrule Rrule">
<p class="First" style="border-left:1px solid;"><span class="XmChange">Withhold trametinib for up to 3 weeks.</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">If improved to Grade 0-1, resume at a lower dose level. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">If not improved, permanently discontinue.</span></dd>
</dl>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">First occurrence of any Grade 4 adverse reaction</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule">
<dl>
<dt>•</dt>
<dd><span class="XmChange">Withhold TAFINLAR until adverse reaction improves to Grade 0-1. Then resume at a lower dose level.</span></dd>
</dl>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Or</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">Permanently discontinue TAFINLAR.</span></dd>
</dl>
</td>
<td class="Botrule Lrule Rrule">
<dl>
<dt>•</dt>
<dd><span class="XmChange">Withhold trametinib until adverse reaction improves to Grade 0-1. Then resume at a lower dose level. </span></dd>
</dl>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Or</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">Permanently discontinue trametinib.</span></dd>
</dl>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="XmChange">Recurrent Grade 4 adverse reaction</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Permanently discontinue TAFINLAR.</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Permanently discontinue trametinib.</span></p></td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Sup">a</span>National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Sup">b</span>See Table 1 for recommended dose reductions of TAFINLAR and trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Sup">c</span>Refer to Full Prescribing Information for trametinib.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_60cae42a-5210-44a2-8797-bc0caeb26af1"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">50 mg Capsules: Dark red capsule imprinted with ‘GS TEW’ and ‘50 mg’.</p>
<p>75 mg Capsules: Dark pink capsule imprinted with ‘GS LHF’ and ‘75 mg’.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_eb612def-e914-42ba-abeb-3507a524167f"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_dc103c82-820a-49b1-a647-ea98945eb87d"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Review the Full Prescribing Information for trametinib prior to initiation of TAFINLAR in combination with trametinib. The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal vein occlusion</span></span></dd>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span></span></dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_246de61f-b61d-4b3e-90d2-307e38395339"></a><a name="section-5.1"></a><p></p>
<h2>5.1 New Primary Malignancies</h2>
<p class="First">New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.</p>
<p><span class="Underline">Cutaneous Malignancies:</span></p>
<p style="border-left:1px solid;">TAFINLAR results in an increased incidence of cutaneous squamous cell carcinoma, <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthoma</span>, and melanoma. <span class="XmChange">TAFINLAR when used in combination with trametinib results in an increased incidence of basal cell carcinoma.</span></p>
<p>In Trial 1, cutaneous squamous cell carcinomas and <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthomas</span> (cuSCC) occurred in 7% (14/187) of patients treated with TAFINLAR and in none of the patients treated with dacarbazine. </p>
<p>Across clinical trials of TAFINLAR (N = 586), the incidence of cuSCC was 11%. The median time to first cuSCC was 9 weeks (range: 1 to 53 weeks). Of those patients who developed new cuSCC, approximately 33% developed one or more cuSCC with continued administration of TAFINLAR. The median time between diagnosis of the first cuSCC and the second cuSCC was 6 weeks.</p>
<p>In Trial 1, the incidence of new primary malignant melanomas was 2% (3/187) for patients receiving TAFINLAR while no dacarbazine-treated patient was diagnosed with new primary malignant melanoma.</p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, the incidence of basal cell carcinoma was increased in patients receiving TAFINLAR in combination with trametinib: 9% (5/55) of patients receiving TAFINLAR in combination with trametinib compared with 2% (1/53) of patients receiving TAFINLAR as a single agent. The range of time to diagnosis of basal cell carcinoma was 28 to 249 days in patients receiving TAFINLAR in combination with trametinib and was 197 days for the patient receiving TAFINLAR as a single agent.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Cutaneous squamous cell carcinoma (SCC), including <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthoma</span>, occurred in 7% of patients receiving TAFINLAR in combination with trametinib and 19% of patients receiving TAFINLAR as a single agent. The range of time to diagnosis of cuSCC was 136 to197 days in the combination arm and was 9 to 197 days in the arm receiving TAFINLAR as a single agent.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">New primary melanoma occurred in 2% (1/53) of patients receiving TAFINLAR as a single agent and in none of the 55 patients receiving TAFINLAR in combination with trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Perform dermatologic evaluations prior to initiation of TAFINLAR as a single agent or in combination with trametinib, every 2 months while on therapy, and for up to 6 months following discontinuation of TAFINLAR. No dose modifications of TAFINLAR or trametinib are required in patients who develop new primary cutaneous malignancies.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Non-cutaneous Malignancies: </span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Based on its mechanism of action, TAFINLAR may promote the growth and development of malignancies with activation of RAS through mutation or other mechanisms <span class="Italics">[see Warnings and Precautions (5.2)]</span>. In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive <span class="product-label-link" type="condition" conceptid="45763891" conceptname="Adenocarcinoma of pancreas">pancreatic adenocarcinoma</span> (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and <span class="product-label-link" type="condition" conceptid="4272187" conceptname="Glioblastoma">glioblastoma</span> (n = 1). Monitor patients receiving the combination closely for signs or symptoms of non-cutaneous malignancies. Permanently discontinue TAFINLAR for RAS mutation-positive non-cutaneous malignancies. If used in combination with trametinib, no dose modification of trametinib is required for patients who develop non-cutaneous malignancies.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3101ce94-a4ac-4a43-9217-49ff3320aadf"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Tumor Promotion in BRAF Wild-Type Melanoma</h2>
<p class="First" style="border-left:1px solid;">In vitro experiments have demonstrated paradoxical activation of MAP-kinase signaling and increased cell proliferation in BRAF wild-type cells which are exposed to BRAF inhibitors. Confirm evidence of BRAF V600E <span class="XmChange">or V600K</span> mutation status prior to initiation of TAFINLAR <span class="XmChange">as</span> a single agent or <span class="XmChange">combination therapy</span><span class="Italics"> [see Indications and Usage (1), Dosage and Administration (2.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_caee0e32-c757-42c4-a6da-592edfb671fe"></a><a name="section-5.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.3 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhages</span>, including major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> defined as symptomatic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in a critical area or organ, can occur when TAFINLAR is used in combination with trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence and severity of any hemorrhagic event: 16% (9/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent. The major hemorrhagic events of intracranial or <span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">gastric hemorrhage</span> occurred in 5% (3/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent. <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial hemorrhage</span> was fatal in 4% (2/55) of patients receiving TAFINLAR in combination with trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Permanently discontinue TAFINLAR and trametinib for all Grade 4 hemorrhagic events and for any Grade 3 hemorrhagic events that do not improve. Withhold TAFINLAR for Grade 3 hemorrhagic events; if improved resume at a lower dose level. Withhold trametinib for up to 3 weeks for Grade 3 hemorrhagic events; if improved, resume at a lower dose level.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_74245e1d-0448-45c3-8b6f-7fff6fbe1853"></a><a name="section-5.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.4 <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span> can occur when TAFINLAR is used in combination with trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> (DVT) and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent. <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> was fatal in 2% (1/55) of patients receiving TAFINLAR in combination with trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Advise patients to immediately seek medical care if they develop symptoms of DVT or PE, such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or arm or leg <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. Permanently discontinue TAFINLAR and trametinib for life-threatening PE. Withhold trametinib and continue TAFINLAR at the same dose for uncomplicated DVT or PE; if improved within 3 weeks, trametinib may be resumed at a lower dose level <span class="Italics">[see Dosage and Administration (2.3)]</span></span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d5ee6127-d7eb-4cbe-a30c-0f960552bd9f"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.5 <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent <span class="Italics">[refer to Full Prescribing Information for trametinib]</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> occurred in 9% (5/55) of patients treated with TAFINLAR in combination with trametinib and in none of patients treated with TAFINLAR as a single agent. The median time to onset of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> in patients treated with TAFINLAR in combination with trametinib was 86 days (range: 27 to 253 days). <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> was identified within the first month of treatment with TAFINLAR in combination with trametinib in two of five patients. Development of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> resolved in all five patients following dose reduction (4/55) and/or dose interruption (1/55). </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), 8% of patients developed evidence of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> (decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF ≥10% below baseline). Two percent demonstrated a decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF of ≥20% below baseline.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Assess LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of TAFINLAR in combination with trametinib, one month after initiation, and then at 2- to 3-month intervals while on treatment with the combination. Withhold treatment with trametinib and continue TAFINLAR at the same dose if absolute LVEF value decreases by 10% from pretreatment values and is less than the lower limit of normal. For symptomatic <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> or persistent, asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue trametinib and withhold TAFINLAR. Resume TAFINLAR at the same dose level upon recovery of cardiac function <span class="Italics">[see Dosage and Administration (2.3)]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eced3634-85be-46cf-8ec1-ee16a00f1a21"></a><a name="section-5.6"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.6 Ocular Toxicities</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Retinal Pigment Epithelial Detachment (RPED):</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Retinal pigment epithelial detachments (RPED) can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent <span class="Italics">[refer to Full Prescribing Information for trametinib]</span>. <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">Retinal detachments</span> resulting from trametinib are often bilateral and multifocal, occurring in the macular region of the retina.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, ophthalmologic examinations including retinal evaluation were performed pretreatment and at regular intervals during treatment. RPED occurred in 2% (1/55) of patients receiving TAFINLAR in combination with trametinib. Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), the incidence of RPED was 1% (2/202). </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Perform ophthalmological evaluation at any time a patient reports <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> and compare with baseline, if available. If TAFINLAR is used in combination with trametinib, do not modify the dose of TAFINLAR. Withhold trametinib if RPED is diagnosed. If resolution of the RPED is documented on repeat ophthalmological evaluation within 3 weeks, resume trametinib at a lower dose level. Discontinue trametinib if no improvement after 3 weeks <span class="Italics">[see Dosage and Administration (2.3)]. </span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> and <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span>:</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> and <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> (including <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>) occurred in 1% (6/586) of patients treated with TAFINLAR as a single agent and <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> occurred in 1% (2/202) of patients treated with TAFINLAR in combination with trametinib. Symptomatic treatment employed in clinical trials included steroid and mydriatic ophthalmic drops. Monitor patients for visual signs and symptoms of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> (e.g., change in vision, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>). If diagnosed, withhold TAFINLAR for up to 6 weeks until <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>/<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> resolves to Grade 0-1. If TAFINLAR is used in combination with trametinib, do not modify the dose of trametinib.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_10722c5d-9921-4c25-9ea2-8fd389f75a34"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Febrile Reactions</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reactions</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of any severity complicated by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib. The incidence and severity of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> are increased when TAFINLAR is used in combination with trametinib compared with TAFINLAR as a single agent <span class="Italics">[see Adverse Reactions (6.1)].</span></span></p>
<p style="border-left:1px solid;">In Trial 1, the incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (serious and non-serious) was 28% in patients treated with TAFINLAR and 10% in patients treated with dacarbazine. In patients treated with TAFINLAR, the median time to initial onset of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (any severity) was 11 days (range: 1 to 202 days) and the median duration of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> was 3 days (range: 1 to 129 days). <span class="XmChange">Serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reactions</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of any severity complicated by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, the incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (serious and non-serious) was 71% (39/55) in patients treated with TAFINLAR in combination with trametinib and 26% (14/53) in patients treated with TAFINLAR as a single agent. Serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reactions</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of any severity complicated by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> was complicated with <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> in 51% (28/55), <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> in 9% (5/55), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> in 4% (2/55), and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in 4% (2/55) of patients in Trial 2.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In patients treated with TAFINLAR in combination with trametinib, the median time to initial onset of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> was 30 days compared with 19 days in patients treated with TAFINLAR as a single agent; the median duration of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> was 6 days with the combination compared with 4 days with TAFINLAR as a single agent.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), the incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> was 57% (116/202).</span></p>
<p style="border-left:1px solid;">Withhold TAFINLAR for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of 101.3ºF or higher. Withhold trametinib for any <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> higher than 104ºF. <span class="XmChange">Withhold TAFINLAR, and trametinib if used in combination, for any serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reaction</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> complicated by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and evaluate for signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Refer to Table 2 for recommended dose modifications for adverse reactions<span class="Italics"> [see Dosage and Administration (2.3)]. </span>Prophylaxis with antipyretics may be required when resuming TAFINLAR or trametinib. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7400742d-d2d3-4b14-a8a5-d6fe2958e080"></a><a name="section-5.8"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.8 Serious Skin Toxicity</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Serious skin toxicity can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent <span class="Italics">[refer to Full Prescribing Information for trametinib]</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, the incidence of any skin toxicity was similar for patients receiving TAFINLAR in combination with trametinib (65% [36/55]) compared with patients receiving TAFINLAR as a single agent (68% [36/53]). The median time to onset of skin toxicity in patients treated with TAFINLAR in combination with trametinib was 37 days (range: 1 to 225 days) and median time to resolution of skin toxicity was 33 days (range: 3 to 421 days). No patient required dose reduction or permanent discontinuation of TAFINLAR or trametinib for skin toxicity.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Across clinical trials of TAFINLAR in combination with trametinib (N = 202), severe skin toxicity and <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infections</span> of the skin requiring hospitalization occurred in 2.5% (5/202) of patients treated with TAFINLAR in combination with trametinib.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Withhold TAFINLAR, and trametinib if used in combination, for intolerable or severe skin toxicity. TAFINLAR and trametinib may be resumed at lower dose levels in patients with improvement or recovery from skin toxicity within 3 weeks <span class="Italics">[see Dosage and Administration (2.3)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d11f3c57-84a6-407f-a170-bdff85815d74"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib</span>.</p>
<p>In Trial 1, 5 of 12 patients with a history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> required more intensive hypoglycemic therapy while taking TAFINLAR. The incidence of Grade 3 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> based on laboratory values was 6% (12/187) in patients treated with TAFINLAR compared with none of the dacarbazine-treated patients.</p>
<p style="border-left:1px solid;"><span class="XmChange">In Trial 2, the incidence of Grade 3 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> based on laboratory values was 5% (3/55) in patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) in patients treated with TAFINLAR as a single agent.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Monitor serum glucose levels as clinically appropriate when TAFINLAR is administered as a single agent or when used in combination with trametinib in patients with pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. Advise patients to report symptoms of severe <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> such as <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">excessive thirst</span> or any increase in the volume or frequency of urination</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_74168113-455a-4c37-8044-695783788ef8"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Glucose-6-Phosphate Dehydrogenase Deficiency</h2>
<p class="First">TAFINLAR, which contains a sulfonamide moiety, confers a potential risk of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Closely observe patients with G6PD deficiency for signs of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6bc15508-c426-4344-a5c7-d5b5b6a1c501"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Embryofetal Toxicity</h2>
<p class="First">Based on its mechanism of action, TAFINLAR can cause fetal harm when administered to a pregnant woman. Dabrafenib was teratogenic and embryotoxic in rats at doses three times greater than the human exposure at the recommended clinical dose. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[see Use in Specific Populations (8.1)]</span>.</p>
<p style="border-left:1px solid;">Advise female patients of reproductive potential to use a highly effective non-hormonal method of contraception since TAFINLAR can render hormonal contraceptives ineffective<span class="XmChange">, during treatment and for at least 2 weeks after treatment with TAFINLAR or for 4 months after treatment with TAFINLAR in combination with trametinib</span>. Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking TAFINLAR <span class="Italics">[see Drug Interactions (7.2), Use in Specific Populations (8.6)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_46abfbf2-ffad-4df0-8079-9ed8798b3296"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in another section of the label:</p>
<dl>
<dt>•</dt>
<dd>New Primary Malignancies <span class="Italics">[see Warnings and Precautions (5.1)]</span>
</dd>
<dt>•</dt>
<dd>Tumor Promotion in BRAF Wild-Type Melanoma <span class="Italics">[see Warnings and Precautions (5.2)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> <span class="Italics">[see Warnings and Precautions (5.5)]</span>
</dd>
<dt>•</dt>
<dd>Ocular Toxicities <span class="Italics">[see Warnings and Precautions (5.6)]</span>
</dd>
<dt>•</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Febrile Reactions</span> <span class="Italics">[see Warnings and Precautions (5.7)]</span>
</dd>
<dt>•</dt>
<dd>Serious Skin Toxicity <span class="Italics">[see Warnings and Precautions (5.8)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> <span class="Italics">[see Warnings and Precautions (5.9)]</span>
</dd>
<dt>•</dt>
<dd>Glucose-6-Phosphate Dehydrogenase Deficiency <span class="Italics">[see Warnings and Precautions (5.10)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bab2577d-bf86-45c1-a1f3-8658c6d2b154"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described in the Warnings and Precautions section and below reflect exposure to TAFINLAR as a single agent and in combination with trametinib.</p>
<p><span class="Underline">BRAF V600E Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span>: </span></p>
<p>The safety of TAFINLAR as a single agent was evaluated in 586 patients with BRAF V600 mutation-positive unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span>, previously treated or untreated, who received TAFINLAR 150 mg orally twice daily until disease progression or unacceptable toxicity, including 181 patients treated for at least 6 months and 86 additional patients treated for more than 12 months. TAFINLAR was studied in open-label, single-arm trials and in an open-label, randomized, active-controlled trial. The median daily dose of TAFINLAR was 300 mg (range: 118 to 300 mg).</p>
<p>Table 3 and Table 4 present adverse drug reactions and laboratory abnormalities identified from analyses of Trial 1 <span class="Italics">[see Clinical Studies (14.1)].</span> Trial 1, a multicenter, international, open-label, randomized (3:1), controlled trial allocated 250 patients with unresectable or metastatic BRAF V600E mutation-positive melanoma to receive TAFINLAR 150 mg orally twice daily (n = 187) or dacarbazine 1,000 mg/m<span class="Sup">2</span> intravenously every 3 weeks (n = 63). The trial excluded patients with abnormal left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> or cardiac valve morphology (≥Grade 2), corrected QT interval ≥480 milliseconds on electrocardiogram, or a known history of glucose-6-phosphate dehydrogenase deficiency. The median duration on treatment was 4.9 months for patients treated with TAFINLAR and 2.8 months for dacarbazine-treated patients. The population exposed to TAFINLAR was 60% male, 99% white, and had a median age of 53 years.</p>
<p>The most commonly occurring adverse reactions (≥20%) in patients treated with TAFINLAR were, in order of decreasing frequency: <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, and palmar-plantar erythrodysesthesia syndrome (PPES).</p>
<p>The incidence of adverse events resulting in permanent discontinuation of study medication in Trial 1 was 3% for patients treated with TAFINLAR and 3% for patients treated with dacarbazine. The most frequent (≥2%) adverse reactions leading to dose reduction of TAFINLAR were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (9%), PPES (3%), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (3%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (2%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2%).<br></p>
<a name="_RefID0EXQAE"></a><table width="100%">
<caption><span>Table 3. Selected Common Adverse Reactions Occurring in ≥10% (All Grades) or ≥2% (Grades 3 or 4) of Patients Treated With TAFINLAR<span class="Sup">a</span></span></caption>
<col width="60%">
<col width="11%">
<col width="9%">
<col width="11%">
<col width="8%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">TAFINLAR</span><br><span class="Bold">N = 187</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">Dacarbazine </span><br><span class="Bold">N = 59</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Primary System Organ Class</span></p>
<p><span class="Bold">Preferred Term</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades (%)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4<span class="Sup">b</span></span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades (%)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
<p><span class="Bold">(%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Skin and subcutaneous tissue disorders</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">Hyperkeratosis</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">37</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA<span class="Sup">f</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA<span class="Sup">f</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Palmar-plantar erythrodysesthesia syndrome</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">32</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">General disorders and administration site conditions</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">27</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Neoplasms benign, malignant, and unspecified (including <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">Papilloma</span><span class="Sup">c</span>
</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">27</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>cuSCC<span class="Sup">d, e</span>
</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Adverse drug reactions, reported using MedDRA and graded using CTCAE version 4.0 for assessment of toxicity.</p>
<p><span class="Sup">b</span>Grade 4 adverse reactions limited to <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span> (n = 1) and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (n = 1).</p>
<p><span class="Sup">c</span>Includes <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">skin papilloma</span> and <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span>.</p>
<p><span class="Sup">d</span>Includes squamous cell carcinoma of the skin and <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthoma</span>.</p>
<p><span class="Sup">e</span>Cases of cutaneous squamous cell carcinoma were required to be reported as Grade 3 per protocol.</p>
<p><span class="Sup">f</span>NA = not applicable.<br></p>
<a name="_RefID0EIABG"></a><table width="100%">
<caption><span>Table 4. Incidence of Laboratory Abnormalities Increased From Baseline Occurring at a Higher Incidence in Patients Treated With TAFINLAR in Trial 1 [Between-Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3 or 4)]</span></caption>
<col width="45%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Test</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR</span></p>
<p><span class="Bold">N = 187</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">DTIC</span></p>
<p><span class="Bold">N = 59</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
<p><span class="Bold">(%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">43</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">37</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">6<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Increased alkaline phosphatase</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Grade 4 laboratory abnormality limited to <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> (n = 1).</p>
<p>Other clinically important adverse reactions observed in &lt;10% of patients (N = 586) treated with TAFINLAR were:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> manifesting as <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rash</span>.</p>
<p><span class="Italics">Renal and Urinary Disorders: </span>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.</p>
<p><span class="Underline">BRAF V600E or V600K Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span>:</span></p>
<p>The safety of TAFINLAR in combination with trametinib was evaluated in Trial 2 and other trials consisting of a total of 202 patients with BRAF V600 mutation-positive unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span> who received TAFINLAR 150 mg orally twice daily in combination with trametinib 2 mg orally once daily until disease progression or unacceptable toxicity. Among these 202 patients, 66 (33%) were exposed to TAFINLAR and 68 (34%) were exposed to trametinib for greater than 6 to 12 months while 40 (20%) were exposed to TAFINLAR and 36 (18%) were exposed to trametinib for greater than one year. The median age was 54 years, 57% were male, and &gt;99% were white.</p>
<p>Table 5 presents adverse reactions from Trial 2, a multicenter, open-label, randomized trial of 162 patients with BRAF V600E or V600K mutation-positive melanoma receiving TAFINLAR 150 mg twice daily in combination with trametinib 2 mg orally once daily (n = 55), TAFINLAR 150 mg orally twice daily in combination with trametinib 1 mg once daily (n = 54), and TAFINLAR as a single agent 150 mg orally twice daily (n = 53) <span class="Italics">[see Clinical Studies (14.2)]</span>. Patients with abnormal LVEF, history of <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> within 6 months, current evidence of Class II or greater <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (New York Heart Association), history RVO or RPED, QTc interval ≥480 msec, treatment <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">refractory hypertension</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, history of <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> or <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, or a known history of G6PD deficiency were excluded. The median duration of treatment was 10.9 months for both TAFINLAR and trametinib (2-mg orally once-daily treatment group) when used in combination, 10.6 months for both TAFINLAR and trametinib (1-mg orally once-daily treatment group) when used in combination, and 6.1 months for TAFINLAR as a single agent.</p>
<p>In Trial 2, 13% of patients receiving TAFINLAR in combination with trametinib experienced adverse reactions resulting in permanent discontinuation of trial medication(s). The most common adverse reaction resulting in permanent discontinuation was <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (4%). Adverse reactions led to dose reductions in 49% and dose interruptions in 67% of patients treated with TAFINLAR in combination with trametinib. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> were the most common reasons cited for dose reductions and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and decreased <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> were the most common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination.</p>
<a name="_RefID0EDKBG"></a><table width="100%">
<caption><span>Table 5. Common Adverse Drug Reactions Occurring in ≥10% at (All Grades) or ≥5% (Grades 3 or 4) of Patients Treated With TAFINLAR in Combination With Trametinib in Trial 2</span></caption>
<col width="25%">
<col width="17%">
<col width="12%">
<col width="17%">
<col width="12%">
<col width="9%">
<col width="8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Adverse Reactions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR plus Trametinib 2 mg</span></p>
<p><span class="Bold">N = 55</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR plus Trametinib 1 mg</span></p>
<p><span class="Bold">N = 54</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR</span></p>
<p><span class="Bold">N = 53</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">All Grades<span class="Sup">a</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">All Grades<span class="Sup">a</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades<span class="Sup">a</span></span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">General disorders and administrative site conditions</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">71</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">69</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">58</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">53</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">57</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span><span class="Sup">b</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Skin and subcutaneous tissue disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">c</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">45</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">43</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">53</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night Sweats</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">Dermatitis acneiform</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic keratosis</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">43</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">36</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><span class="Sup">d</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">37</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Musculoskeletal, connective tissue, and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">34</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Metabolism and nutritional disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span><span class="Sup">e</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Renal and urinary disorders</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span><span class="Sup">f</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.</p>
<p><span class="Sup">b</span>Includes the following terms: <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>.</p>
<p><span class="Sup">c</span>Includes the following terms: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span>, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular.</p>
<p><span class="Sup">d</span>Includes the following terms: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>.</p>
<p><span class="Sup">e</span>Includes the following terms: <span class="product-label-link" type="condition" conceptid="4319328" conceptname="Brain stem hemorrhage">brain stem hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">gastric hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, gingival <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">hemorrhage intracranial</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="315276" conceptname="Vitreous hemorrhage">vitreous hemorrhage</span>.</p>
<p><span class="Sup">f</span>Includes the following terms: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">renal failure acute</span>.</p>
<p>Other clinically important adverse reactions (N = 202) observed in &lt;10% of patients treated with TAFINLAR in combination with trametinib were:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span>, <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">transient blindness</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">rash pustular</span>.</p>
<p><span class="Italics">Neoplasms Benign, Malignant, and Unspecified (including <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>): </span><span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">Skin papilloma</span>.</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> Palmar-plantar erythrodysesthesia syndrome, <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>.</p>
<a name="_RefID0EASAI"></a><table width="100%">
<caption><span>Table 6. Treatment-Emergent Laboratory Abnormalities Occurring at ≥10% (All Grades) or ≥2% (Grades 3 or 4)] of Patients Treated With TAFINLAR in Combination With Trametinib in Trial 2 </span></caption>
<col width="35%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="8%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Tests</span></p></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR plus Trametinib 2 mg</span></p>
<p><span class="Bold">N = 55</span></p>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR plus Trametinib 1 mg</span></p>
<p><span class="Bold">N = 54</span></p>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR</span></p>
<p><span class="Bold">N = 53</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">All</span></p>
<p><span class="Bold">Grades</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Grades</span></p>
<p><span class="Bold">3 and 4<span class="Sup">a</span></span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Hematology</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span> </dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">59</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">37</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0 </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Liver Function Tests</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	Increased AST</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">54</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	Increased alkaline phosphatase</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">67</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	Increased ALT</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Bold">Chemistry</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">58</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">67</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">49</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	Increased GGT</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">56</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">54</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">38</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">48</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">36</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">53</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">43</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">47</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">41</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	Increased creatinine</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>	<span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>No Grade 4 events were reported in patients receiving TAFINLAR as a single agent.</p>
<p>ALT = <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span>; AST = <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span>; GGT = Gamma glutamyltransferase.</p>
<p><span class="Underline">QT Prolongation:</span> In Trial 2, QTcF prolongation to &gt;500 msec occurred in 4% (2/55) of patients treated with TAFINLAR in combination with trametinib and in 2% (1/53) of patients treated with TAFINLAR as a single agent. The QTcF was increased more than 60 msec from baseline in 13% (7/55) of patients treated with TAFINLAR in combination with trametinib and 2% (1/53) of patients treated with TAFINLAR as a single agent. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_c91ce6a4-0981-47e9-b11a-b2368bf3c1d0"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5be5734d-a26e-465f-b84b-411935911d37"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effects of Other Drugs on Dabrafenib</h2>
<p class="First">Dabrafenib is primarily metabolized by CYP2C8 and CYP3A4. Strong inhibitors of CYP3A4 or CYP2C8 may increase concentrations of dabrafenib and strong inducers of CYP3A4 or CYP2C8 may decrease concentrations of dabrafenib <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. Substitution of strong inhibitors or strong inducers of CYP3A4 or CYP2C8 is recommended during treatment with TAFINLAR. If concomitant use of strong inhibitors (e.g., ketoconazole, nefazodone, clarithromycin, gemfibrozil) or strong inducers (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, St John’s wort) of CYP3A4 or CYP2C8 is unavoidable, monitor patients closely for adverse reactions when taking strong inhibitors or loss of efficacy when taking strong inducers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e4fbfff8-381d-41cc-8829-4f644defb184"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effects of Dabrafenib on Other Drugs</h2>
<p class="First">Dabrafenib induces CYP3A4 and CYP2C9. Dabrafenib decreased the systemic exposures of midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), and R-warfarin (a CYP3A4/CYP1A2 substrate) <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. Monitor international normalized ratio (INR) levels more frequently in patients receiving warfarin during initiation or discontinuation of dabrafenib. Coadministration of TAFINLAR with other substrates of these enzymes, including dexamethasone or hormonal contraceptives<span class="Italics">, </span>can result in decreased concentrations and loss of efficacy <span class="Italics">[see Use in Specific Populations (8.1, 8.6)]</span>. Substitute for these medications or monitor patients for loss of efficacy if use of these medications is unavoidable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_190dba17-e8da-4137-824e-963c51155283"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Trametinib</h2>
<p class="First">Coadministration of TAFINLAR 150 mg twice daily and trametinib 2 mg once daily resulted in no clinically relevant pharmacokinetic drug interactions <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_a5269422-757f-46b2-a697-8b42e3913f66"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_af99b01e-2247-48c2-8aef-cc255145d414"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D</p>
<p><span class="Underline">Risk Summary:</span> Based on its mechanism of action, TAFINLAR can cause fetal harm when administered to a pregnant woman. Dabrafenib was teratogenic and embryotoxic in rats at doses three times greater than the human exposure at the recommended clinical dose of 150 mg twice daily based on AUC. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[see Warnings and Precautions (5.11)]</span>.</p>
<p><span class="Underline">Animal Data:</span> In a combined female fertility and embryofetal development study in rats, developmental toxicity consisted of embryo-lethality, <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span>, and variation in thymic shape at a dabrafenib dose of 300 mg/kg/day (approximately three times the human exposure at the recommended dose based on AUC). At doses of 20 mg/kg/day or greater (equivalent to the human exposure at the recommended dose based on AUC), rats demonstrated delays in skeletal development and reduced fetal body weight.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_47509c9d-0d8e-44d3-bad3-26b7e98dc215"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is present in human milk. Because many drugs are present in human milk and because of the potential for serious adverse reactions from TAFINLAR in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_2bdd6e6f-7e52-4d7b-b83f-a93ecd64099c"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of TAFINLAR have not been established in pediatric patients.</p>
<p>In a repeat-dose toxicity study in juvenile rats, an increased incidence of kidney <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and tubular deposits were noted at doses as low as 0.2 times the human exposure at the recommended adult dose based on AUC. Additionally, forestomach <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, decreased bone length and early vaginal opening were noted at doses as low as 0.8 times the human exposure at the recommended adult dose based on AUC.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_3c3140f5-21af-4663-944c-8d8fc6f63bdc"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">One hundred and twenty-six (22%) of 586 patients in clinical trials of TAFINLAR administered as a single agent and 40 (21%) of the 187 patients receiving TAFINLAR in Trial 1 were ≥65 years of age. No overall differences in the effectiveness or safety of TAFINLAR were observed in the elderly in Trial 1.</p>
<p>Across all clinical trials of TAFINLAR administered in combination with trametinib, there was an insufficient number of patients aged 65 years and over to determine whether they respond differently from younger patients. In Trial 2, 11 patients (20%) were 65 years of age and older, and 2 patients (4%) were 75 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3a52d010-5f75-4401-be38-dd1b79b4ccec"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Females and Males of Reproductive Potential</h2>
<p class="First"><span class="Underline">Contraception:</span><span class="Italics">Females:</span> Advise female patients of reproductive potential to use highly effective contraception during treatment and for at least 2 weeks after the last dose of TAFINLAR or at least 4 months after the last dose of TAFINLAR taken in combination with trametinib. Counsel patients to use a non-hormonal method of contraception since TAFINLAR can render hormonal contraceptives ineffective. Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking TAFINLAR <span class="Italics">[see Warnings and Precautions (5.11), Drug Interactions (7.1), Use in Specific Populations (8.1)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span>:</span></p>
<p><span class="Italics">Females:</span> Increased follicular <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and decreased corpora lutea were observed in female rats treated with trametinib. Advise female patients of reproductive potential that TAFINLAR taken in combination with trametinib may impair fertility in female patients.</p>
<p><span class="Italics">Males:</span> Effects on spermatogenesis have been observed in animals. Advise male patients of the potential risk for impaired spermatogenesis, and to seek counseling on fertility and family planning options prior to starting treatment with TAFINLAR <span class="Italics">[see Nonclinical Toxicology (13.1)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b37d9598-a4f9-4f5b-b1ff-b2a66047ad16"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No formal pharmacokinetic trial in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has been conducted. Dose adjustment is not recommended for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> based on the results of the population pharmacokinetic analysis. As hepatic metabolism and biliary secretion are the primary routes of elimination of dabrafenib and its metabolites, patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may have increased exposure. An appropriate dose has not been established for patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_584503b4-2fd3-450b-9a9b-a7c1562d9da4"></a><a name="section-8.7"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No formal pharmacokinetic trial in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been conducted. Dose adjustment is not recommended for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> based on the results of the population pharmacokinetic analysis. An appropriate dose has not been established for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_51962ae7-4c57-48a7-a60c-3c510c7e6d38"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no information on overdosage of TAFINLAR. Since dabrafenib is highly bound to plasma proteins, hemodialysis is likely to be ineffective in the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with TAFINLAR.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_7aed8d30-c0c2-4360-9528-3c54df2e2cd6"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt. It has the molecular formula C<span class="Sub">23</span>H<span class="Sub">20</span>F<span class="Sub">3</span>N<span class="Sub">5</span>O<span class="Sub">2</span>S<span class="Sub">2</span>•CH<span class="Sub">4</span>O<span class="Sub">3</span>S and a molecular weight of 615.68. Dabrafenib mesylate has the following chemical structure.</p>
<div class="Figure">
<a name="id1960634"></a><img alt="dabrafenib mesylate chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4&amp;name=tafinlar-spl-graphic-01.jpg">
</div>
<p>Dabrafenib mesylate is a white to slightly colored solid with three pK<span class="Sub">a</span>s: 6.6, 2.2, and -1.5. It is very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.</p>
<p>TAFINLAR (dabrafenib) capsules are supplied as 50-mg and 75-mg capsules for oral administration. Each 50-mg capsule contains 59.25 mg dabrafenib mesylate equivalent to 50 mg of dabrafenib free base. Each 75-mg capsule contains 88.88 mg dabrafenib mesylate equivalent to 75 mg of dabrafenib free base.</p>
<p>The inactive ingredients of TAFINLAR are colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. Capsule shells contain hypromellose, red iron oxide (E172), and titanium dioxide (E171).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_396f979a-70fe-44cb-bfb3-3da0e68afc42"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_54fece58-ebe5-45b2-84d8-0cb876890b86"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC<span class="Sub">50</span> values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC<span class="Sub">50</span> values of 3.2 and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth <span class="Italics">[see Indications and Usage (1)]</span>. Dabrafenib inhibits BRAF V600 mutation-positive melanoma cell growth in vitro and in vivo.</p>
<p>Dabrafenib and trametinib target two different tyrosine kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_acbdc2c7-4fb7-4ccd-b1d3-d6477edb0d2b"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption: </span>After oral administration, median time to achieve peak plasma concentration (Tmax) is 2 hours. Mean absolute bioavailability of oral dabrafenib is 95%. Following a single dose, dabrafenib exposure (Cmax and AUC) increased in a dose-proportional manner across the dose range of 12 to 300 mg, but the increase was less than dose-proportional after repeat twice-daily dosing. After repeat twice-daily dosing of 150 mg, the mean accumulation ratio was 0.73 and the inter-subject variability (CV%) of AUC at steady-state was 38%.</p>
<p>Administration of dabrafenib with a high-fat meal decreased C<span class="Sub">max </span>by 51%, decreased AUC by 31%, and delayed median T<span class="Sub">max</span> by 3.6 hours as compared with the fasted state <span class="Italics">[see Dosage and Administration (2.2)]</span>.</p>
<p><span class="Underline">Distribution:</span> Dabrafenib is 99.7% bound to human plasma proteins. The apparent volume of distribution (V<span class="Sub">c</span>/F) is 70.3 L.</p>
<p><span class="Underline">Metabolism:</span> The metabolism of dabrafenib is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-dabrafenib. Hydroxy-dabrafenib is further oxidized via CYP3A4 to form carboxy-dabrafenib and subsequently excreted in bile and urine. Carboxy-dabrafenib is decarboxylated to form desmethyl-dabrafenib; desmethyl-dabrafenib may be reabsorbed from the gut. Desmethyl-dabrafenib is further metabolized by CYP3A4 to oxidative metabolites. Hydroxy-dabrafenib terminal half-life (10 hours) parallels that of dabrafenib while the carboxy- and desmethyl-dabrafenib metabolites exhibited longer half-lives (21 to 22 hours). Mean metabolite-to-parent AUC ratios following repeat-dose administration are 0.9, 11, and 0.7 for hydroxy-, carboxy-, and desmethyl-dabrafenib, respectively. Based on systemic exposure, relative potency, and pharmacokinetic properties, both hydroxy- and desmethyl-dabrafenib are likely to contribute to the clinical activity of dabrafenib.</p>
<p><span class="Underline">Elimination:</span> The mean terminal half-life of dabrafenib is 8 hours after oral administration. The apparent clearance of dabrafenib is 17.0 L/h after single dosing and 34.4 L/h after 2 weeks of twice-daily dosing.</p>
<p>Fecal excretion is the major route of elimination accounting for 71% of radioactive dose while urinary excretion accounted for 23% of total radioactivity as metabolites only.</p>
<p><span class="Underline">Specific Populations: </span></p>
<p><span class="Italics">Age, Body Weight, and Gender:</span> Based on the population pharmacokinetics analysis, age has no effect on dabrafenib pharmacokinetics. Pharmacokinetic differences based on gender and on weight are not clinically relevant.</p>
<p><span class="Italics">Pediatric:</span> Pharmacokinetics of dabrafenib has not been studied in pediatric <span class="Italics">patients.</span></p>
<p><span class="Italics">Renal:</span> No formal pharmacokinetic trial in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been conducted. The pharmacokinetics of dabrafenib were evaluated using a population analysis in 233 patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR 60 to 89 mL/min/1.73 m<span class="Sup">2</span>) and 30 patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR 30 to 59 mL/min/1.73 m<span class="Sup">2</span>) enrolled in clinical trials. Mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has no effect on systemic exposure to dabrafenib and its metabolites. No data are available in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Italics">Hepatic:</span> No formal pharmacokinetic trial in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has been conducted. The pharmacokinetics of dabrafenib was evaluated using a population analysis in 65 patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> enrolled in clinical trials. Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has no effect on systemic exposure to dabrafenib and its metabolites. No data are available in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Underline">Drug Interactions:</span></p>
<p>In vitro studies show that dabrafenib is a substrate of CYP3A4 and CYP2C8 while hydroxy-dabrafenib and desmethyl-dabrafenib are CYP3A4 substrates. Coadministration of dabrafenib 75 mg twice daily and ketoconazole 400 mg once daily (a strong CYP3A4 inhibitor) for 4 days increased dabrafenib AUC by 71%, hydroxy-dabrafenib AUC by 82%, and desmethyl-dabrafenib AUC by 68%. Coadministration of dabrafenib 75 mg twice daily and gemfibrozil 600 mg twice daily (a strong CYP2C8 inhibitor) for 4 days increased dabrafenib AUC by 47%, with no change in the AUC of dabrafenib metabolites. Dabrafenib is a substrate of human P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in vitro.</p>
<p>In vitro data demonstrate that dabrafenib is an inducer of CYP3A4 and CYP2B6 via activation of the pregnane X receptor (PXR) and constitutive androstane receptor (CAR) nuclear receptors. Dabrafenib may also induce CYP2C enzymes via the same mechanism. Coadministration of dabrafenib 150 mg twice daily for 15 days and a single dose of midazolam 3 mg (a CYP3A4 substrate) decreased midazolam AUC by 74%. Coadministration of dabrafenib 150 mg twice daily for 15 days and a single dose of warfarin 15 mg decreased the AUC of S-warfarin (a CYP2C9 substrate) by 37% and the AUC of R-warfarin (a CYP3A4/CYP1A2 substrate) by 33% <span class="Italics">[see Drug Interactions (7.2)]</span>.</p>
<p>Dabrafenib and its metabolites, hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib, are inhibitors of human organic anion transporting polypeptide OATP1B1, OATP1B3 and organic anion transporter OAT1 and OAT3 in vitro. Dabrafenib and desmethyl-dabrafenib are inhibitors of BCRP in vitro.</p>
<p>Coadministration of trametinib 2 mg daily with dabrafenib 150 mg twice daily resulted in a 23% increase in AUC of dabrafenib, a 33% increase in AUC of desmethyl-dabrafenib, and no change in AUC of trametinib or hydroxy-dabrafenib as compared with administration of either drug alone.</p>
<p>Drugs that alter the pH of the upper GI tract (e.g., proton pump inhibitors, H<span class="Sub">2</span>-receptor antagonists, antacids) may alter the solubility of dabrafenib and reduce its bioavailability. However, no formal clinical trial has been conducted to evaluate the effect of gastric pH-altering agents on the systemic exposure of dabrafenib. When TAFINLAR is coadministered with a proton pump inhibitor, H<span class="Sub">2</span>-receptor antagonist, or antacid, systemic exposure of dabrafenib may be decreased and the effect on efficacy of TAFINLAR is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_7307882b-09f1-4e53-a0d9-4502103a2c4c"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_3c054557-6b03-4298-80f5-c19d08c4df3e"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies with dabrafenib have not been conducted. TAFINLAR increased the risk of cutaneous squamous cell carcinomas in patients in clinical trials.</p>
<p>Dabrafenib was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test) or the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and was not clastogenic in an in vivo rat bone marrow micronucleus test.</p>
<p>In a combined female fertility and embryofetal development study in rats, a reduction in fertility was noted at doses greater than or equal to 20 mg/kg/day (equivalent to the human exposure at the recommended dose based on AUC). A reduction in the number of ovarian corpora lutea was noted in pregnant females at 300 mg/kg/day (which is approximately three times the human exposure at the recommended dose based on AUC).</p>
<p>Male fertility studies with dabrafenib have not been conducted; however, in repeat-dose studies, testicular degeneration/depletion was seen in rats and dogs at doses equivalent to and three times the human exposure at the recommended dose based on AUC, respectively.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_894e0042-c987-42d0-b6bd-853442b47381"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Adverse cardiovascular effects were noted in dogs at dabrafenib doses of 50 mg/kg/day (approximately five times the human exposure at the recommended dose based on AUC) or greater, when administered for up to 4 weeks. Adverse effects consisted of coronary arterial degeneration/<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, as well as cardiac atrioventricular valve <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>/<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_245134b6-324e-4024-9b30-aa1d63062ac0"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a176681f-f182-4e19-823d-6ec3504dc811"></a><a name="section-13.1"></a><p></p>
<h2>14.1 BRAF V600E Mutation-Positive Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></h2>
<p class="First">In Trial 1, the safety and efficacy of TAFINLAR as a single agent were demonstrated in an international, multicenter, randomized (3:1), open-label, active-controlled trial conducted in 250 patients with previously untreated BRAF V600E mutation-positive, unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span>. Patients with any prior use of BRAF inhibitors or MEK inhibitors were excluded. Patients were randomized to receive TAFINLAR 150 mg orally twice daily (n = 187) or dacarbazine 1,000 mg/m<span class="Sup">2</span> intravenously every 3 weeks (n = 63). Randomization was stratified by disease stage at baseline [unresectable stage III (regional nodal or in-transit <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>), M1a (distant skin, subcutaneous, or nodal <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>), or M1b (lung <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>) versus M1c melanoma (all other visceral <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> or elevated serum LDH)]. The main efficacy outcome measure was progression-free survival (PFS) as assessed by the investigator. In addition, an independent radiology review committee (IRRC) assessed the following efficacy outcome measures in pre-specified supportive analyses: PFS, confirmed objective response rate (ORR), and duration of response.</p>
<p>The median age of patients in Trial 1 was 52 years. The majority of the trial population was male (60%), white (99%), had an ECOG performance status of 0 (67%), M1c disease (66%), and normal LDH (62%). All patients had tumor tissue with mutations in BRAF V600E as determined by a clinical trial assay at a centralized testing site. Tumor samples from 243 patients (97%) were tested retrospectively, using an FDA-approved companion diagnostic test, THxID™-BRAF assay.</p>
<p>The median durations of follow-up prior to initiation of alternative treatment in patients randomized to receive TAFINLAR was 5.1 months and in the dacarbazine arm was 3.5 months. Twenty-eight (44%) patients crossed over from the dacarbazine arm at the time of disease progression to receive TAFINLAR.</p>
<p>Trial 1 demonstrated a statistically significant increase in progression-free survival in the patients treated with TAFINLAR. Table 7 and Figure 1 summarize the PFS results.</p>
<a name="_RefID0ER3BI"></a><table width="100%">
<caption><span>Table 7. Investigator-Assessed Progression-Free Survival and Confirmed Objective Response Results in Trial 1</span></caption>
<col width="54%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">TAFINLAR</span></p>
<p><span class="Bold">N = 187</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Dacarbazine</span></p>
<p><span class="Bold">N = 63</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Progression-free Survival</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Number of Events (%)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">78 (42%)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">41 (65%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Progressive Disease</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">76</p></td>
<td class="Lrule Rrule" align="center"><p class="First">41</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Median, months (95% CI)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.1 (4.9, 6.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.7 (1.5, 3.2)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>HR<span class="Sup">a</span> (95% CI)</dd>
</dl></td>
<td class="Lrule Rrule" align="center" colspan="2"><p class="First">0.33 (0.20, 0.54)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>
<span class="Italics">P</span>-value<span class="Sup">b</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Italics">P </span>&lt;0.0001</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Confirmed Tumor Responses</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Objective Response Rate</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">52%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">17%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>(95% CI)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">(44, 59)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(9, 29)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>CR, n (%)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6 (3%)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>PR, n (%)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">91 (48%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11 (17%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Duration of Response</dd>
</dl></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Median, months (95% CI)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.6 (5.4, NR)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NR (5.0, NR)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Pike estimator, stratified by disease state.</p>
<p><span class="Sup">b</span>Stratified log-rank test.</p>
<p>CI = Confidence interval; CR = Complete response; HR = Hazard ratio; NR = Not reached; PR = Partial response.</p>
<p><span class="Bold">Figure 1. Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival </span></p>
<div class="Figure">
<a name="id15267056"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4&amp;name=tafinlar-spl-graphic-02.jpg">
</div>
<p>In supportive analyses based on IRRC assessment and in an exploratory subgroup analysis of patients with retrospectively confirmed V600E mutation-positive melanoma with the THxID™-BRAF assay, the PFS results were consistent with those of the primary efficacy analysis.</p>
<p>The activity of TAFINLAR for the treatment of BRAF V600E mutation-positive melanoma, metastatic to the brain was evaluated in a single-arm, open-label, two-cohort multi-center trial (Trial 3). All patients received TAFINLAR 150 mg twice daily. Patients in Cohort A (n = 74) had received no prior local therapy for <span class="product-label-link" type="condition" conceptid="378087" conceptname="Secondary malignant neoplasm of brain and spinal cord">brain metastases</span>, while patients in Cohort B (n = 65) had received at least one local therapy for <span class="product-label-link" type="condition" conceptid="378087" conceptname="Secondary malignant neoplasm of brain and spinal cord">brain metastases</span>, including, but not limited to, surgical resection, whole brain radiotherapy, or stereotactic radiosurgery such as gamma knife, linear-accelerated-based radiosurgery, charged particles, or CyberKnife. In addition, patients in Cohort B were required to have evidence of disease progression in a previously treated lesion or an untreated lesion. Additional eligibility criteria were at least one measurable lesion of 0.5 cm or greater in largest diameter on contrast-enhanced MRI, stable or decreasing corticosteroid dose, and no more than two prior systemic regimens for treatment of <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>. The primary outcome measure was estimation of the overall intracranial response rate (OIRR) in each cohort. </p>
<p>The median age of patients in Cohort A was 50 years, 72% were male, 100% were white, 59% had a pre-treatment ECOG performance status of 0, and 57% had an elevated LDH value at baseline. The median age of patients in Cohort B was 51 years, 63% were male, 98% were white, 66% had a pre-treatment ECOG performance status of 0, and 54% had an elevated LDH value at baseline. Efficacy results as determined by an independent radiology review committee, masked to investigator response assessments, are provided in Table 8.</p>
<a name="_Ref353885831"></a><table width="100%">
<caption><span>Table 8. Efficacy Results in Patients With BRAF V600E Melanoma <span class="product-label-link" type="condition" conceptid="378087" conceptname="Secondary malignant neoplasm of brain and spinal cord">Brain Metastases</span> (Trial 3)</span></caption>
<col width="59%">
<col width="21%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Endpoint</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">IRRC Assessed Response</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Cohort A</span></p>
<p><span class="Bold">N = 74</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Cohort B</span></p>
<p><span class="Bold">N = 65</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Overall Intracranial Response Rate (OIRR)</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>% (95% CI)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">18 (9.7, 28.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">18 (9.9, 30.0)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Duration of OIRR</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(N = 13)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(N = 12)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Median, months </p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>(95% CI)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.6 (2.8, NR)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.6 (1.9, 4.6)</p></td>
</tr>
</tbody>
</table>
<p>IRRC = Independent radiology review committee; CI = Confidence interval; NR = Not reached.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_83860c45-251c-4b14-9e9e-a02f51f26845"></a><a name="section-13.2"></a><p></p>
<h2>14.2 BRAF V600E or V600K Unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">Metastatic Melanoma</span></h2>
<p class="First">Trial 2 was a multicenter, open-label, randomized (1:1:1) dose-ranging trial designed to evaluate the clinical activity and safety of TAFINLAR in combination with trametinib (at two different doses) and to compare the safety with TAFINLAR as a single agent in 162 patients with BRAF V600E or V600K mutation-positive, unresectable or <span class="product-label-link" type="condition" conceptid="40481908" conceptname="Metastatic malignant melanoma">metastatic melanoma</span>. Patients were permitted to have had one prior chemotherapy regimen and prior aldesleukin; patients with prior exposure to BRAF or MEK inhibitors were ineligible. Patients were randomized to receive TAFINLAR 150 mg orally twice daily with trametinib 2 mg orally once daily (n = 54), TAFINLAR 150 mg orally twice daily with trametinib 1 mg orally once daily (n = 54), or TAFINLAR 150 mg orally twice daily (n = 54). Treatment continued until disease progression or unacceptable toxicity. Patients randomized to TAFINLAR as a single agent were offered TAFINLAR 150 mg orally twice daily with trametinib 2 mg orally once daily at the time of investigator-assessed disease progression. The major efficacy outcome measure was investigator-assessed overall response rate (ORR). Additional efficacy outcome measures were investigator-assessed duration of response, independent radiology review committee (IRRC)-assessed ORR, and IRRC-assessed duration of response.</p>
<p>The median age of patients was 53 years, 57% were male, &gt;99% were white, 66% of patients had a pre-treatment ECOG performance status of 0, 67% had M1c disease, 54% had a normal LDH at baseline, and 8% had history of <span class="product-label-link" type="condition" conceptid="378087" conceptname="Secondary malignant neoplasm of brain and spinal cord">brain metastases</span>. Most patients (81%) had not received prior anti-cancer therapy for unresectable or <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>. Based on local laboratory or centralized testing, 85% of patients’ tumors had BRAF V600E mutations and 15% had BRAF V600K mutations.</p>
<p>The median duration of follow-up was 14 months. Efficacy outcomes for the trial arms receiving TAFINLAR in combination with trametinib 2 mg orally once daily and TAFINLAR as a single agent are summarized in Table 9.</p>
<a name="_RefID0EBLCI"></a><table width="100%">
<caption><span>Table 9. Investigator-Assessed and Independent Review Committee-Assessed Response Rates and Response Duration in Trial 2 </span></caption>
<col width="42%">
<col width="39%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Endpoints</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR plus Trametinib</span></p>
<p><span class="Bold">N = 54</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">TAFINLAR</span></p>
<p><span class="Bold">N = 54</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Investigator Assessment</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Responders (ORR%)</span></p>
<dl>
<dt> </dt>
<dd>(95% CI)</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">41 (76%)</p>
<p>(62%, 87%) </p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">29 (54%)</p>
<p>(40%, 67%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Complete response</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Partial response</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">67%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Duration of Response (months)</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Median </dd>
<dt> </dt>
<dd>(95% CI)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">10.5</p>
<p>(7, 15)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">5.6</p>
<p>(5, 7)</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Independent Radiology Review Committee Assessment</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Responders (ORR%)</span></p>
<dl>
<dt> </dt>
<dd>(95% CI)</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">31 (57%)</p>
<p>(43%, 71%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">25 (46%)</p>
<p>(33%, 60%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Complete response</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Partial response</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">48%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">39%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Duration of Response (months)</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Median</dd>
<dt> </dt>
<dd>(95% CI)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">7.6</p>
<p>(7, NR)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">7.6</p>
<p>(6, NR)</p>
</td>
</tr>
</tbody>
</table>
<p>CI = Confidence interval; ORR = Confirmed overall response rate; NR = Not reported. </p>
<p>The ORR results were similar in subgroups defined by BRAF mutation subtype, i.e., in the 85% of patients with V600E mutation-positive melanoma and in the 15% of patients with V600K mutation-positive melanoma. In exploratory subgroup analyses of the patients with retrospectively confirmed BRAF V600E or V600K mutation-positive melanoma using the THxID<span class="Sup">™</span>-BRAF assay, the ORR results were also similar to the intent-to-treat analysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_2ff9aece-8fad-463d-9328-af32d7a62337"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">50 mg Capsules: Dark red capsule imprinted with ‘GS TEW’ and ‘50 mg’ available in bottles of 120 (NDC 0173-0846-08). Each bottle contains a silica gel desiccant.</p>
<p>75 mg Capsules: Dark pink capsule imprinted with ‘GS LHF’ and ‘75 mg’ available in bottles of 120 (NDC 0173-0847-08). Each bottle contains a silica gel desiccant.</p>
<p>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_9d4623a4-5a67-4e47-9c12-b4269f5a2170"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Medication Guide).</p>
<p>Inform patients of the following:</p>
<dl>
<dt>•</dt>
<dd>Evidence of BRAF V600E mutation in the tumor specimen is necessary to identify patients for whom treatment with TAFINLAR as a single agent is indicated and evidence of BRAF V600E or V600K mutation in tumor specimens is necessary to identify patients for whom treatment with TAFINLAR in combination with trametinib is indicated <span class="Italics">[see Dosage and Administration (2.1)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR increases the risk of developing new primary cutaneous and non-cutaneous malignancies. Advise patients to contact their doctor immediately for any new lesions, changes to existing lesions on their skin, or signs and symptoms of other malignancies <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR administered in combination with trametinib increases the risk of intracranial and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>. Advise patients to contact their healthcare provider to seek immediate medical attention for signs or symptoms of unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR administered in combination with trametinib increases the risks of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>. Advise patients to seek immediate medical attention for sudden onset of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR administered in combination with trametinib can cause <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. Advise patients to immediately report any signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> to their healthcare provider <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR can cause <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; TAFINLAR administered in combination with trametinib can lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>. Advise patients to contact their healthcare provider if they experience any changes in their vision <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR administered as a single agent and in combination with trametinib, can cause <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> including serious <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reactions</span>. Inform patients that the incidence and severity of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> are increased when TAFINLAR is given in combination with trametinib. Instruct patients to contact their doctor if they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> while taking TAFINLAR <span class="Italics">[see Warnings and Precautions (5.7)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR in combination with trametinib can cause serious skin toxicities which may require hospitalization. Advise patients to contact their healthcare provider for progressive or intolerable <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see Warnings and Precautions (5.8</span>)<span class="Italics">].</span>
</dd>
<dt>•</dt>
<dd>TAFINLAR can impair glucose control in diabetic patients resulting in the need for more intensive hypoglycemic treatment. Advise patients to contact their doctor to report symptoms of severe <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> <span class="Italics">[see Warnings and Precautions (5.9)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR may cause <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Advise patients with known G6PD deficiency to contact their doctor to report signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> <span class="Italics">[see Warnings and Precautions (5.10)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR can cause fetal harm if taken during pregnancy. Instruct female patients to use non-hormonal, highly effective contraception during treatment and for 2 weeks after discontinuation of treatment with TAFINLAR as a single agent, or for 4 months after discontinuation of treatment with TAFINLAR in combination with trametinib. Advise patients to contact their doctor if they become pregnant, or if pregnancy is suspected, while taking TAFINLAR <span class="Italics">[see Warnings and Precautions (5.11), Use in Specific Populations (8.1)</span>].</dd>
<dt>•</dt>
<dd>Nursing infants may experience serious adverse reactions if the mother is taking TAFINLAR during breastfeeding. Advise breastfeeding mothers to discontinue nursing while taking TAFINLAR <span class="Italics">[see Use in Specific Populations (8.3)]</span>.</dd>
<dt>•</dt>
<dd>Male patients are at an increased risk for impaired spermatogenesis <span class="Italics">[see Use in Specific Populations (8.6)]</span>.</dd>
<dt>•</dt>
<dd>TAFINLAR should be taken either at least 1 hour before or at least 2 hours after a meal <span class="Italics">[see Dosage and Administration (2.1)]</span>.</dd>
</dl>
<p>TAFINLAR is a registered trademark of the GlaxoSmithKline group of companies.</p>
<p>THxID™ is a trademark of bioMérieux.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>©2014, GlaxoSmithKline group of companies. All rights reserved.</p>
<p>TFR:4PI<br></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_395e15e7-1c90-4b0f-813e-9cef20d4d356"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">TAFINLAR</span><span class="Sup">®</span><span class="Bold"> (TAFF-in-lar)</span></p>
<p><span class="Bold">(dabrafenib)</span></p>
<p><span class="Bold">capsules</span></p>
<p>If your healthcare provider prescribes TAFINLAR for you in combination with trametinib, also read the Patient Information leaflet that comes with trametinib.</p>
<p><span class="Bold">What is the most important information I should know about TAFINLAR?</span></p>
<p><span class="Bold">TAFINLAR may cause serious side effects, including the risk of new cancers:</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">TAFINLAR, when used alone or in combination with trametinib, may cause a type of skin cancer, called cutaneous squamous cell carcinoma (cuSCC). New melanoma lesions have also occurred in people who take TAFINLAR.</span></dd>
<dt>•</dt>
<dd><span class="Bold">TAFINLAR, in combination with trametinib, may cause new cancers including basal cell carcinoma.</span></dd>
</dl>
<p>Talk with your healthcare provider about your risk for these cancers.</p>
<p><span class="Bold">Check your skin and tell your healthcare provider right away about any skin changes including a:</span></p>
<dl>
<dt>•</dt>
<dd>new <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span></dd>
<dt>•</dt>
<dd>skin sore or reddish bump that bleeds or does not heal</dd>
<dt>•</dt>
<dd>change in size or color of a mole</dd>
</dl>
<p>Your healthcare provider should check your skin before you start taking TAFINLAR, and every two months while taking TAFINLAR to look for any new skin cancers. Your healthcare provider may continue to check your skin for six months after you stop taking TAFINLAR.</p>
<p>Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that have developed while taking TAFINLAR in combination with trametinib.</p>
<p>See “What are the possible side effects of TAFINLAR?? for more information about side effects.</p>
<p><span class="Bold">What is TAFINLAR?</span></p>
<p>TAFINLAR is a prescription medicine used alone or in combination with trametinib to treat people with a type of skin cancer called melanoma:</p>
<dl>
<dt>•</dt>
<dd>that has spread to other parts of the body or cannot be removed by surgery, and</dd>
<dt>•</dt>
<dd>that has a certain type of abnormal “BRAF? gene.</dd>
</dl>
<p>Your healthcare provider will perform a test to make sure that TAFINLAR is right for you.</p>
<p>TAFINLAR (alone or in combination with trametinib) is not used to treat people with a type of skin cancer called wild-type BRAF melanoma.</p>
<p>It is not known if TAFINLAR is safe and effective in children.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking TAFINLAR?</span></p>
<p><span class="Bold">Before you take TAFINLAR, tell your healthcare provider if you:</span></p>
<dl>
<dt>•</dt>
<dd>have had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems or blood clots</dd>
<dt>•</dt>
<dd>have heart problems</dd>
<dt>•</dt>
<dd>have eye problems</dd>
<dt>•</dt>
<dd>have liver or kidney problems</dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>•</dt>
<dd>plan to have surgery, dental, or other medical procedures</dd>
<dt>•</dt>
<dd>have a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme</dd>
<dt>•</dt>
<dd>have any other medical conditions </dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. TAFINLAR can harm your unborn baby.<dl>
<dt>•</dt>
<dd>Females who are able to become pregnant should use birth control (contraception) <span class="Bold">during treatment</span> with TAFINLAR <span class="Bold">and</span> for <span class="Bold">2 weeks after stopping</span> treatment with <span class="Bold">TAFINLAR alone, or</span> for <span class="Bold">4 months when taking TAFINLAR in combination with trametinib.</span>
</dd>
<dt>•</dt>
<dd>Birth control using hormones (such as birth control pills, injections, or patches) may not work as well while you are taking TAFINLAR alone or in combination with trametinib. You should use another effective method of birth control while taking TAFINLAR alone or in combination with trametinib.</dd>
<dt>•</dt>
<dd>Talk to your healthcare provider about birth control methods that may be right for you during this time.</dd>
<dt>•</dt>
<dd>Tell your healthcare provider right away if you become pregnant during treatment with TAFINLAR alone or in combination with trametinib.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if TAFINLAR passes into your breast milk. You and your healthcare provider should decide if you will take TAFINLAR or breastfeed. You should not do both.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAFINLAR and certain other medicines can affect each other, causing side effects. TAFINLAR may affect the way other medicines work, and other medicines may affect how TAFINLAR works. You can ask your pharmacist for a list of medicines that may interact with TAFINLAR.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take TAFINLAR?</span></p>
<dl>
<dt>•</dt>
<dd>Take TAFINLAR exactly as your healthcare provider tells you. Do not change your dose or stop TAFINLAR unless your healthcare provider tells you.</dd>
<dt>•</dt>
<dd>Take TAFINLAR 2 times a day, about 12 hours apart.</dd>
<dt>•</dt>
<dd>If you take TAFINLAR in combination with trametinib, take the first dose of TAFINLAR in the morning, and take the second dose of TAFINLAR in the evening, about 12 hours apart. Take trametinib 1 time a day at the same time each day, either with the morning or the evening dose of TAFINLAR.</dd>
<dt>•</dt>
<dd>Take TAFINLAR at least 1 hour before or 2 hours after a meal.</dd>
<dt>•</dt>
<dd>Do not open, crush, or break TAFINLAR capsules.</dd>
<dt>•</dt>
<dd>If you miss a dose of TAFINLAR, take it as soon as you remember. But, if it is within 6 hours of your next scheduled dose, just take your next dose at your regular time. Do not make up for the missed dose. </dd>
<dt>•</dt>
<dd>If you are taking TAFINLAR in combination with trametinib and you miss a dose of trametinib, take it as soon as you remember. But, if it is within 12 hours of your next scheduled dose of trametinib, just take your next dose at your regular time. Do not make up for the missed dose.</dd>
<dt>•</dt>
<dd>If you take too much TAFINLAR, call your healthcare provider or go to the nearest hospital emergency room right away.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of TAFINLAR?</span></p>
<p><span class="Bold">TAFINLAR may cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">See “What is the most important information I should know about TAFINLAR??</span></dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems.</span> TAFINLAR, in combination with trametinib, can cause serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems,especially in your brain or stomach, and can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Call your healthcare provider and get medical help right away if you have any unusual signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or feeling weak</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up blood or blood clots</dd>
<dt>•</dt>
<dd>vomit blood or your vomit looks like “coffee grounds?</dd>
<dt>•</dt>
<dd>red or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> that look like tar</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">blood clots.</span> TAFINLAR, in combination with trametinib, can cause blood clots in your arms or legs, which can travel to your lungs and can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Get medical help right away if you have the following symptoms:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></dd>
<dt>•</dt>
<dd>sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your legs with or without <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your arms or legs</dd>
<dt>•</dt>
<dd>a cool or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> arm or leg</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">heart problems, including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span> Your healthcare provider should check your heart function before you start taking TAFINLAR in combination with trametinib and during treatment. Call your healthcare provider right away if you have any of the following signs and symptoms of a heart problem:<dl>
<dt>•</dt>
<dd>feeling like your heart is pounding or racing</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your ankles and feet</dd>
<dt>•</dt>
<dd>feeling lightheaded</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">eye problems.</span> TAFINLAR alone, or in combination with trametinib, can cause severe eye problems that can lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>. Call your healthcare provider right away if you get these symptoms of eye problems:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or other vision changes</dd>
<dt>•</dt>
<dd>see color dots</dd>
<dt>•</dt>
<dd>halo (seeing blurred outline around objects)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. </span>TAFINLAR alone or in combination with trametinib can cause <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> which may be serious. When taking TAFINLAR, in combination with trametinib, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> may happen more often or may be more severe. In some cases, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, too much <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or kidney problems may happen with the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Call your healthcare provider right away if you get a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> while taking TAFINLAR.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> is a common side effect of TAFINLAR alone, or when used in combination with trametinib. TAFINLAR alone, or in combination with trametinib, can also cause other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.  In some cases these <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> and other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> can be severe, and may need to be treated in a hospital. Call your healthcare provider if you get any of the following symptoms:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> that bothers you or does not go away</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> of hands or feet</dd>
<dt>•</dt>
<dd>skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">increased blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>).</span> Some people may develop high blood sugar or worsening <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> during treatment with TAFINLAR, alone or in combination with trametinib. If you are diabetic, your healthcare provider should check your blood sugar levels closely during treatment with TAFINLAR alone or in combination with trametinib. Your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine may need to be changed. Tell your healthcare provider if you have any of the following symptoms of severe high blood sugar:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span></dd>
<dt>•</dt>
<dd>urinating more often than normal, or urinating an increased amount of urine</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">TAFINLAR may cause healthy red blood cells to break down too early in people with G6PD deficiency.</span> This may lead to a type of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> called <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> where the body does not have enough healthy red blood cells. Tell your healthcare provider if you have any of the following signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or breakdown of red blood cells:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4021666" conceptname="Yellow skin">yellow skin</span> (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
</dl>
</dd>
</dl>
<p><span class="Bold">The most common side effects of TAFINLAR when used alone include:</span></p>
<dl>
<dt>•</dt>
<dd>thickening of the outer layers of the skin</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> of hands or feet</dd>
</dl>
<p><span class="Bold">Common side effects of TAFINLAR when used in combination with trametinib include:</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>•</dt>
<dd>stomach-area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, arms, or legs</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>•</dt>
<dd>muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span></dd>
</dl>
<p>TAFINLAR, in combination with trametinib, may cause fertility problems in females. This could affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.</p>
<p>TAFINLAR may cause lower sperm counts in males. This could affect the ability to father a child. Talk to your healthcare provider if this is a concern for you. </p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of TAFINLAR. For more information about side effects, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p>You may also report side effects to GlaxoSmithKline at 1-888-825-5249.</p>
<p><span class="Bold">How should I store TAFINLAR?</span></p>
<p>Store TAFINLAR at room temperature, between 68°F to 77°F (20°C to 25°C).</p>
<p><span class="Bold">Keep TAFINLAR and all medicine out of the reach of children.</span></p>
<p><span class="Bold">General information about TAFINLAR</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TAFINLAR for a condition for which it was not prescribed. Do not give TAFINLAR to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>You can ask your healthcare provider or pharmacist for information about TAFINLAR that is written for health professionals. </p>
<p>For more information, call GlaxoSmithKline at 1-888-825-5249 or go to www.TAFINLAR.com.</p>
<p><span class="Bold">What are the ingredients in TAFINLAR?</span></p>
<p><span class="Bold">Active ingredient:</span> dabrafenib</p>
<p><span class="Bold">Inactive ingredients:</span> colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose</p>
<p>Capsule shells: hypromellose, red iron oxide (E172), titanium dioxide (E171).</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Revised: January 2014</p>
<p>TAFINLAR is a registered trademark of the GlaxoSmithKline group of companies.</p>
<p>©2014, GlaxoSmithKline group of companies. All rights reserved.</p>
<p>TFR:3MG</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_ee154590-d2a5-412b-a4d2-224bb2714363"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel</span></p>
<p><span class="Bold">NDC 0173-0846-08</span></p>
<p><span class="Bold">Tafinlar<span class="Sup">®</span></span></p>
<p>(Dabrafenib) Capsules</p>
<p><span class="Bold">50 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p>120 Capsules</p>
<p><span class="Bold">Federal Law requires dispensing of TAFINLAR<span class="Sup">®</span> with the Medication Guide provided with this bottle.</span></p>
<p>Each capsule contains 59.25 mg dabrafenib mesylate equivalent to 50 mg dabrafenib.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>Store at 25°C (77°F); excursions permitted 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold">Do not use if printed safety seal under cap is broken or missing.</span></p>
<p>GlaxoSmithKline</p>
<p>RTP, NC 27709</p>
<p>10000000124205	Rev. 3/14</p>
<div class="Figure">
<a name="id9988250"></a><img alt="Tafinlar 50mg 120 count label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4&amp;name=tafinlar-spl-graphic-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_20511432-0e56-449a-a880-1be6de8f77d3"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel</span></p>
<p><span class="Bold">NDC 0173-0847-08</span></p>
<p><span class="Bold">Tafinlar<span class="Sup">®</span></span></p>
<p>(Dabrafenib) Capsules</p>
<p><span class="Bold">75 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p>120 Capsules</p>
<p><span class="Bold">Federal Law requires dispensing of TAFINLAR<span class="Sup">®</span> with the Medication Guide provided with this bottle.</span></p>
<p>Each capsule contains 88.88 mg dabrafenib mesylate equivalent to 75 mg dabrafenib.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>Store at 25°C (77°F); excursions permitted 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold">Do not use if printed safety seal under cap is broken or missing.</span></p>
<p>GlaxoSmithKline</p>
<p>RTP, NC 27709</p>
<p>10000000124207	Rev. 3/14</p>
<div class="Figure">
<a name="id9988471"></a><img alt="Tafinlar 75mg 120 count label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4&amp;name=tafinlar-spl-graphic-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TAFINLAR 		
					</strong><br><span class="contentTableReg">dabrafenib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0846</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DABRAFENIB MESYLATE</strong> (DABRAFENIB) </td>
<td class="formItem">DABRAFENIB</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GSTEW;50mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0846-08</td>
<td class="formItem">120  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/10/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202806</td>
<td class="formItem">06/10/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TAFINLAR 		
					</strong><br><span class="contentTableReg">dabrafenib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0847</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DABRAFENIB MESYLATE</strong> (DABRAFENIB) </td>
<td class="formItem">DABRAFENIB</td>
<td class="formItem">75 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GSLHF;75mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0847-08</td>
<td class="formItem">120  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/10/2013</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0173-0847-61</td>
<td class="formItem">28  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/10/2013</td>
<td class="formItem">12/11/2014</td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0173-0847-65</td>
<td class="formItem">56  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">10/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202806</td>
<td class="formItem">06/10/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>GlaxoSmithKline LLC
							(167380711)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5d77ada8-474c-4d16-8619-6f99dfdc44f4</div>
<div>Set id: 803beaaa-33f9-48cc-9a95-c2e887e095b4</div>
<div>Version: 9</div>
<div>Effective Time: 20140113</div>
</div>
</div> <div class="DistributorName">GlaxoSmithKline LLC</div></p>
</body></html>
